Kalytera Therapeutics Inc . (TSX: V.KALY, OTCQB: KALTF, Forum) on Thursday announced a major step forward in its program to develop the first cannabinoid-derived pain treatment targeting activation of alpha3 glycine receptors.
More information can be foundhere.
The Companywas in the news recentlywhen it stated that it will defer milestone payments to the former shareholders of Talent Biotechs, Ltd. of Israel, for patents acquired around cannabidiol treatments for graft versus host disease.
FULL DISCLOSURE: Kalytera Therapeutics Inc. is a paid client of Stockhouse Publishing.